Hyderabad has emerged as the Indian city with the highest incidence of breast cancer, according to recent data from the National Cancer Registry Programme (NCRP). While the finding is striking, oncologists and hospital leaders warn that it is less an outlier than a glimpse into what other major cities may soon face. Rising urban lifestyle risks, limited screening uptake, and late diagnoses are converging to make breast cancer India’s most common cancer among women.

A Shifting Epidemiological Landscape

NCRP data places Hyderabad at the top of India’s breast cancer incidence, with age-adjusted rates estimated at nearly 54 cases per 100,000 women. That figure is significantly higher than national averages, which range between 30–35 per 100,000 in most urban registries. The surge comes against a backdrop of rising overall cancer burden in India - with ICMR projecting annual cancer cases to cross 1.57 million by 2030, nearly a fifth of which will be breast cancers.

Unlike cervical cancer, whose incidence has fallen due to better awareness and vaccination campaigns, breast cancer has shown a consistent upward trajectory in Indian cities. Globally, too, breast cancer has become the most commonly diagnosed cancer among women, overtaking lung cancer in some regions. Hyderabad’s data reflects both improved detection infrastructure and a real shift in risk exposure, highlighting the challenges that Indian metros face as they urbanize.

Urban Lifestyle Risks: The Changing Drivers

“Breast cancer has emerged as the most common cancer among Indian women, and cities like Hyderabad are seeing this trend more acutely due to rapid urbanization, lifestyle changes, delayed childbearing, and lack of awareness around routine screening,” says Dr. Niti Krishna Raizada, Principal Director of Medical Oncology at Fortis Hospital, Bengaluru. She also points to the city’s large migrant population - many families come to Hyderabad for cancer treatment because it is an IT hub, which further contributes to the high numbers reported.

Dr. K.M.M. Vishvak Chanthar, Chief of Breast Surgical Oncology at RGCIRC, similarly emphasizes that “sedentary lifestyles, obesity, alcohol consumption, delayed childbearing, and reduction in breastfeeding are contributing factors to the increased incidence.” These are consistent with international evidence showing that metabolic risk factors and reproductive patterns drive higher rates of post-menopausal breast cancer.

Hyderabad’s rapid growth as an IT and services hub has accelerated these shifts. Later marriage, fewer children, and shorter breastfeeding duration - once rare in Indian contexts - are increasingly common. Added to this are dietary changes, stress, and physical inactivity. “The trend in Hyderabad reflects what is likely to be seen in other urban centres if preventive measures are not scaled quickly,” says Dr. Deepak Jha, Chief – Breast Surgery at Artemis Hospitals.

Dr. Pragnya Chigurupati, Consultant in Breast Health at Fernandez Stork Home, Hyderabad, notes another concerning development: “Though enhanced detection partially accounts for the increase, lifestyle, hereditary, and environmental causes are fueling an alarming rise in women in their 30s and 40s. Genetic susceptibility, particularly BRCA1/2 mutations, also puts younger women at risk.” She adds that researchers are increasingly studying the impact of environmental and dietary factors, including endocrine-disrupting chemicals, on incidence trends.

The city’s data also suggests the “urban registry effect”: more advanced diagnostic infrastructure leads to more cancers being picked up, earlier and more often. Dr. Bhavisha Ghugare of HCG Cancer Centre explains that while incidence appears higher, part of the rise is due to greater screening and reporting. “But lifestyle and reproductive patterns remain the fundamental drivers,” she cautions.

The Screening Gap

Despite advances, breast cancer in India is still largely diagnosed at late stages. National surveys suggest that fewer than 30 per cent of women over 40 undergo any form of routine screening. In rural and semi-urban areas, the figure is substantially lower.

Hospitals in Hyderabad and elsewhere are responding with outreach programmes. Artemis Hospitals runs mobile vans and corporate awareness camps. SSO Cancer Hospital operates a mobile mammography unit that has already conducted over 1,000 screenings in underserved communities. “The need of the hour is to make cancer a notifiable disease across India,” says Dr. Jay Anam, Director at SSO Cancer Hospital. “This will ensure accurate data collection and better policy planning.”

At Fernandez Stork Home, initiatives include a dedicated breast clinic offering consultation, imaging, biopsy, counselling, and follow-up. The Breast Health Express run by the Government of Telangana, a mobile mammography and ultrasound bus, travels across rural Telangana to provide free screening and awareness camps. “Thousands of women can now get screened near their homes by trained professionals,” says Dr. Pragnya.

At HCG, structured preventive oncology services are being rolled out, including lifestyle counselling, risk stratification, and age-appropriate screening plans. However, cultural barriers remain. As Dr. Dhanalakshmi of SIMS Hospital in Chennai notes, “many women still hesitate to come forward for screening due to lack of knowledge or stigma. This is something that requires constant work and repeated awareness campaigns.”

Dr. Raizada of Fortis stresses that hospitals carry a “dual responsibility” - not just delivering advanced treatment, but also building preventive ecosystems. “Only through this integrated approach - awareness, access, and advanced care - can we hope to change the trajectory of breast cancer in India,” she says.

Advances in Detection and Treatment

The good news is that technology is transforming outcomes. Digital mammography, 3D tomosynthesis, MRI-based screening for high-risk women, and targeted ultrasound are improving small-lesion detection. Genetic testing for BRCA mutations is slowly gaining ground, allowing closer surveillance of high-risk populations.

“Stage 1 breast cancer can often be managed with surgery and limited therapy, with excellent outcomes,” says Dr. Dhanalakshmi. “But late-stage disease requires aggressive chemotherapy, radiotherapy, and multiple surgeries, with higher recurrence risk.”

Treatment is also evolving rapidly. Oncoplastic breast surgery, sentinel lymph node biopsy, and breast-conserving techniques are replacing mutilating mastectomies. “We can now pursue lumpectomy with reconstruction in many cases, preserving both survival and vitality,” says Dr. Vishvak Chanthar.

Dr. Pragnya highlights that oncoplastic surgery and multidisciplinary tumour boards are helping deliver more personalised care, while international innovations like molecular profiling are tailoring therapies to tumour biology.

Advances in systemic therapy - HER2-targeted drugs, CDK4/6 inhibitors, and immunotherapy for triple-negative disease - are extending survival and improving quality of life. “Targeted therapies, immunotherapy, and minimally invasive surgical approaches are transforming treatment outcomes,” adds Dr. Raizada.

Radiotherapy has also become safer and shorter. Hypofractionated protocols reduce hospital visits, while deep-inspiration breath-hold techniques minimize cardiac exposure in left-sided cancers. “These advances reduce not just mortality but also long-term morbidity,” notes Dr. Ghugare.

Policy, Infrastructure, and Cost

The Telangana government has announced district-level cancer centres as part of the Union Budget 2025 mandate to establish day-care oncology centres across India. These facilities could improve access to diagnosis and treatment in smaller towns, reducing the load on Hyderabad’s tertiary hospitals.

Affordability, however, remains a barrier. Pharmaceuticals account for nearly 35 per cent of a typical hospital cancer bill. Here, recent GST reforms are relevant. As Dr. Shuchin Bajaj of Ujala Cygnus Healthcare has argued, reducing GST on stents, cancer drugs, and diagnostics will lower treatment costs. The exemption of health insurance premiums from GST could also expand financial protection, crucial given that only 41 per cent of households currently have any health cover.

Private insurers and aggregators like Policybazaar are beginning to design oncology-specific products. Still, out-of-pocket expenditure remains high - WHO estimates that nearly 20 per cent of cancer patients in India face catastrophic health spending.

Hyderabad as a Case Study for Urban India

Experts emphasize that Hyderabad’s position at the top of the registry is not an isolated anomaly but a reflection of India’s broader urban health trajectory. “Lifestyle changes are happening everywhere, and prevention and early detection must be a priority across India,” says Dr. Dhanalakshmi.

Dr. Anam points out that tertiary centres in major metros also attract patients from nearby states, inflating local registry numbers. But he cautions against complacency: “What Hyderabad teaches us is that without systemic screening, cancers will continue to present late, driving both costs and mortality.”

Industry and Investor Implications

The rising burden of breast cancer is shaping India’s healthcare economy in multiple ways:

• Hospitals are investing in oncology centres, imaging suites, and mobile screening units.
• Pharma is expanding oncology pipelines - breast cancer drugs represent one of the fastest-growing therapeutic segments, with double-digit annual growth.
• MedTech firms see opportunities in AI-enabled mammography, biopsy devices, and reconstruction implants. Telangana has even piloted AI-based screening tools to augment radiologist capacity.
• Insurance is moving from niche riders to integrated oncology products, reflecting both demand and regulatory push.

For investors, the oncology ecosystem is becoming a top M&A theme. In 2024 alone, Sun Pharma acquired an oncology asset for $355 million, and Mankind Pharma bought Bharat Serums for $1.64 billion, partly for its oncology portfolio.

Looking Ahead: The Next Decade

India’s breast cancer challenge is both clinical and systemic. Clinically, survival rates are improving with early detection and advanced therapies. Systemically, however, gaps in awareness, screening coverage, and financial protection remain.

“Obesity, delayed pregnancies, and stress will continue to drive incidence upward,” says Dr. Jha. “But with organized screening and access to modern therapies, mortality can be reduced significantly.”

As Hyderabad shows, urban India is at the frontline of this epidemiological shift. Hospitals, policymakers, and industry must act in tandem - expanding screening, rationalizing costs, and accelerating innovation. The choice is between treating rising numbers of late-stage cancers or investing upfront in prevention and early detection.

In the words of Dr. Ghugare: “Most breast cancers are curable, especially when found early. The challenge is ensuring that women come forward, get screened, and receive treatment without delay.”